Physician profile
Eric A Albert
NPI 1811642077
$2,099.33
in general payments reported to CMS, 2019-2025
20 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $387 · 2023: $971 · 2024: $632 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $347.20 | 2023-2025 | Watchman Access System, Watchman Flx, Accolade Sr |
| Amgen INC. | $302.50 | 2022-2024 | Repatha |
| Cvrx, INC. | $288.80 | 2022-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $277.31 | 2022-2024 | Verquvo |
| Pfizer INC. | $173.19 | 2022-2024 | |
| Philips North America LLC | $133.04 | 2023 | |
| Novartis Pharmaceuticals Corporation | $108.26 | 2023-2024 | |
| Medtronic, INC. | $105.99 | 2023 | Cg Future |
| Kestra Medical Technology Services, INC. | $69.56 | 2023-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals Lp | $42.66 | 2023-2024 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $42.65 | 2024 | Xarelto |
| Inspire Medical Systems, INC. | $36.68 | 2023-2024 | Inspire |
| Scpharmaceuticals INC. | $31.82 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.25 | 2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $22.78 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, Ltd. | $20.99 | 2023 | Arcalyst |
| W. L. Gore & Associates, INC. | $20.07 | 2025 | Gore Cardioform Septal Occluder |
| Kiniksa Pharmaceuticals International, Plc | $18.10 | 2024 | Arcalyst |
| Abiomed | $17.99 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.49 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.